Granules India gains after arm receives EIR from USFDA for Virginia facility

Granules India rose 1.69% to Rs 789.95 after its arm, Granules Pharmaceuticals Inc. (GPI), received an Establishment Inspection Report (EIR) from the USFDA with a Voluntary Action Indicated (VAI) classification for its Virginia, USA facility.

The USFDA conducted an inspection of the facility from 30 March to 3 April 2026 and issued four Form 483 observations. The receipt of the EIR with a VAI classification indicates the successful closure of the inspection.

The company said the facility remains an important part of its global manufacturing and supply network, with continued focus on quality systems, regulatory compliance, and patient safety.

Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). The company?s consolidated net profit climbed 32.58% to Rs 201.56 crore on 22.81% increase in revenue from operations to Rs 1,470.60 crore in Q4 FY26 over Q4 FY25.

Powered by Capital Market - Live News